Hanmi holds third symposium for Amosartan

Published: 2012-07-11 06:56:00

Updated: 2012-07-11 06:56:00

Hanmi Pharmaceutical Co. said that it has successfully completed its nationwide symposium for Amosartan, hypertension combination drug combination drug of amlodipine camsylate and losartan potassium, between May 22 and 26 to commemorate the drug’s third launching anniversary with around 1,100 Korean doctors

Company officials said the symposium provided an opportunity to seek a new insights i...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.